Figure 3
Kaplan-Meier survival analysis of Aurora-A expression in subsets of NSCLC patients with different stage. (A) Probability of overall survival and (B) progression-free survival of NSCLC patients with stage I in the testing set: low expression, n = 6; high expression, n = 5. (C) Probability of overall survival and (D) progression-free survival of NSCLC patients with stage II in the testing set: low expression, n = 16; high expression, n = 8. (E) Probability of overall survival and (F) progression-free survival of NSCLC patients with stage III in the testing set: low expression, n = 23; high expression, n = 44.